Company Overview
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-throughput gene-editing system marketed under the Trait Machine brand name. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Why Investors Should Care
Revenue has grown at a 11.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $3.64M (-14.6% YoY); net profit $-127.08M.
- Trailing 12 Months Year-on-year growth — revenue +6.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.08% |
| 1 Year: | 6.50% |
Stock Price Performance
| 1 Year: | +13.38% |
| 6 Months: | -56.25% |
| 3 Months: | +30.89% |
| 1 Month: | -11.05% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.61 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.1% over 5 years.
CONS
- Trading 60.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CBUS Cibus, Inc. PHARMA | 1.61 | -1.07 | $123.05M | 0.00% | -33.84% | - | 11.08% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 55.00K | 223.00K | 44.00K | 186.00K | 11.00K | 196.00K | 27.00K | 2.00K | 157.00K | 408.00K | 2.97M | 3.76M | 2.38M | 2.31M | 5.24M | 4.40M | 11.88M | 7.76M | 32.00K | 41.00K | 42.00K | 42.00K | 197.00K | 475.00K | 545.00K | 838.00K | 1.67M | 1.03M | 933.00K | 615.00K | 1.68M |
| Gross Profit | - | - | - | - | - | - | 11.00K | 196.00K | 27.00K | 2.00K | 123.00K | 105.00K | -561.00K | -1.65M | -1.51M | -3.01M | -1.82M | -2.34M | 353.00K | -519.00K | 32.00K | 41.00K | 42.00K | 42.00K | - | - | - | - | - | - | - | - | - |
| Operating Income | -2.49M | -2.48M | -2.79M | -3.24M | -12.95M | - | -4.30M | -7.49M | -7.70M | - | -7.52M | -9.49M | -10.69M | - | -10.65M | -11.05M | -9.05M | -9.68M | -5.98M | -6.96M | -6.09M | -6.76M | -6.20M | -4.46M | -19.31M | -25.80M | -18.45M | -21.48M | -200.44M | -41.57M | -17.95M | -15.44M | -12.12M |
| Net Income | -2.46M | -2.51M | -2.83M | -3.40M | -12.90M | -6.85M | -4.37M | -7.58M | -7.48M | -8.47M | -7.38M | -9.40M | -10.67M | -12.16M | -11.06M | -10.90M | -9.48M | -10.03M | -4.81M | -7.31M | -5.62M | -2.48M | -5.95M | -5.39M | -18.69M | -26.43M | -23.43M | -24.88M | -179.97M | -46.89M | -25.37M | -23.54M | -21.22M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.13 | -0.20 | -1.34 | -2.66 | -6.36 | -5.46 | -3.05 | -1.59 | -1.12 | -1.14 | -7.63 | -1.34 | -0.61 | -0.44 | -0.33 |
| R&D Expense | 1.31M | 1.24M | 1.27M | 1.45M | 6.44M | - | 1.05M | 3.24M | 3.44M | - | 2.22M | 2.74M | 3.58M | - | 2.79M | 2.83M | 2.20M | 3.05M | 2.84M | 2.58M | 2.94M | 3.25M | 3.02M | 2.21M | 8.43M | 17.52M | 12.01M | 12.99M | 12.99M | 11.80M | 12.23M | 10.78M | 8.72M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.27M | 399.00K | 508.00K | 236.00K | 7.30M | 23.85M | 25.99M | 157.00K | 1.82M | 4.26M | 3.64M |
| Gross Profit | - | - | 508.00K | 236.00K | -1.98M | -11.28M | -2.57M | 157.00K | - | - | - |
| Operating Income | -5.81M | -12.11M | -25.79M | -28.11M | -39.67M | -43.83M | -29.33M | -22.37M | -318.88M | -258.40M | -97.53M |
| Net Income | -5.89M | -12.09M | -25.98M | -27.90M | -39.61M | -44.84M | -29.20M | -16.89M | -267.63M | -251.39M | -127.08M |
| Diluted EPS | - | - | - | - | - | -1.32 | -0.78 | -18.36 | -25.95 | -10.83 | -2.78 |
| R&D Expense | 2.77M | 5.64M | 11.51M | 10.36M | 12.21M | 11.08M | 11.34M | 11.55M | 42.37M | 50.43M | 44.20M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 16.62M | 72.17M | 118.79M | 88.10M | 63.33M | 37.19M | 22.42M | 544.41M | 350.07M | 305.05M |
| Total Equity | -10.44M | 24.26M | 13.12M | 57.48M | 93.40M | 62.51M | 36.88M | 14.13M | 7.23M | 293.47M | 92.16M | 21.83M |
| Cash & Equivalents | 303.00K | 24.69M | 5.03M | 56.66M | 93.79M | 58.61M | 17.30M | 13.82M | 3.43M | 32.70M | 14.43M | 9.92M |
| Long Term Debt | - | - | - | - | - | - | 1.52M | 0 | 0 | 536.00K | 226.00K | 93.00K |
| Total Liabilities | - | - | 3.50M | 14.69M | 25.39M | 25.59M | 26.45M | 23.06M | 15.19M | 206.12M | 252.24M | 283.22M |
| Current Liabilities | - | - | 2.87M | 4.25M | 7.00M | 7.20M | 6.95M | 4.85M | 1.66M | 21.32M | 19.88M | 16.86M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | -9.24M | -12.79M | -20.20M | -31.95M | -43.67M | -18.81M | -19.36M | -46.21M | -58.04M | -50.59M |
| Investing Cash Flow | - | -10.42M | -779.00K | -1.85M | -2.97M | -13.48M | 11.20M | -1.52M | 55.06M | -808.00K | -578.00K |
| Financing Cash Flow | - | - | 65.20M | 60.67M | -330.00K | 15.41M | 3.74M | 9.99M | 20.32M | 40.60M | 46.65M |
| Capital Expenditure | -665.00K | -10.42M | -779.00K | -1.85M | -2.97M | -1.79M | -497.00K | -1.52M | -4.32M | -808.00K | -578.00K |
| Free Cash Flow | - | -19.66M | -13.56M | -22.05M | -34.92M | -45.46M | -19.31M | -20.88M | -50.53M | -58.85M | -51.17M |
| Share Buybacks | - | - | - | 200.00K | 800.00K | - | - | - | - | - | - |
| Dividends Paid | 110.00K | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 100.0% | 100.0% | -27.2% | -47.3% | -9.9% | 100.0% | - | - | - |
| Operating Margin % | -457.1% | -3,034.8% | -5,076.6% | -11,913.1% | -543.8% | -183.8% | -112.9% | -14,248.4% | -17,550.0% | -6,062.8% | -2,680.1% |
| Net Margin % | -463.0% | -3,029.1% | -5,114.2% | -11,820.8% | -542.9% | -188.0% | -112.4% | -10,758.6% | -14,729.1% | -5,898.4% | -3,492.3% |
| ROE % | -24.3% | -92.1% | -45.2% | -29.9% | -63.4% | -121.6% | -206.6% | -233.5% | -91.2% | -272.8% | -582.2% |
| ROCE % | - | -88.0% | -38.0% | -25.2% | -49.0% | -77.7% | -90.7% | -107.8% | -61.0% | -78.3% | -33.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.98% | 11.45M | $18.43M |
| 2 | Vanguard Capital Management LLC | 3.01% | 2.30M | $3.70M |
| 3 | United Capital Financial Advisors, LLC | 0.75% | 576.04K | $927.43K |
| 4 | Geode Capital Management, LLC | 0.69% | 528.23K | $850.46K |
| 5 | Blackrock Inc. | 0.64% | 492.80K | $793.40K |
| 6 | Certior Financial Group, LLC | 0.44% | 337.71K | $543.71K |
| 7 | Prescott Group Capital Management, L.L.C. | 0.43% | 328.16K | $528.33K |
| 8 | Squarepoint Ops LLC | 0.41% | 312.34K | $502.87K |
| 9 | Vanguard Fiduciary Trust Co | 0.41% | 310.14K | $499.32K |
| 10 | Corient Private Wealth LP | 0.22% | 164.97K | $265.61K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CBUS
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates - Eastern Progress
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOSHdkbklBa1ZBM20zQk44TVRvSElpTGxWR2ZOVFljMXBrVmR3Q3AtbTZuckk5cGJsMHo5b2czTkNsVW9vQWdXZXFET1gxSkJTekVTUlcxNU85UzNsMWhSc0lCeXRBN0k3M1duS1hlTXd5SFhzaWdDRk83X1FRTk9SOGJKM2RxanhJRzVMRW…
Cibus (CBUS) Upgraded to Buy: What Does It Mean for the Stock? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQNDFjZldKaEF0eEl1c0g5X2xaMHU1c0thenhRM0hZaWtZdzQ3TU0yTzZQZGxyQTYzT2lMakpCT2I3WjBGWFR2M0NwTDhZY0lITmpMVVBON2w4ODhrSkRPMU5ETmt1RExXLXcydWZLb0VmQjlTWTNOWFRkVDJYTFRfdjBvVG9Sd2VMU1VIem…
CBUS Stock Price and Chart — NASDAQ:CBUS - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9td3g5UFZBbEdqZjRNQVJOMFNMazhaYmRvQ2lmaUxtNlQ0YXNGMzVWQ0ltanEyd296YTRmdXNWUmtuMXM4dFp0TFBFbXFNNnBwdlRZbC1lNHpUeGFh?oc=5" target="_blank">CBUS Stock Price and Chart — NASDAQ:CBUS</a…
CIBUS ($CBUS) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE5ocGlZZXpySlVIaUx3ZW5DMkd5NVdMeXJ2bXdUY09fNXV0RG9fY2I3S1RNUFNXX3BiRHJzVlN0VENJWjRsSldDMTc4S2pQTVIyNmFOYzlqQTlWR3lpb1FvNVE0czJUeUpTMTROcE5ER0Q1ZG9XLXZuZG9lakc?oc=5" target="_blank">…
Cibus helps farmers grow more food with fewer inputs; Aug. 13 webcast - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxONHdVQjhQdG9UcDQwTG9scWRBaUsyYjRvaHl4V29COTUzVXRrQ1NOTk9lR2xsNmxxRjN1ajFsd2ZYZXRYU0dETkZvejVrLVdJQ3RTWnM1UGxhTXFjcEJieWpBaVZXb21XTHJGU0xSd3ZBRWdlX2FtZXpWQktnakR4OXFSWFQyYkx3WTdaQV…
Cibus Inc (CBUS) Earnings Date & Reports & Earnings News - TradingKey
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE9xSjNrT0U1S09Ucnh5RmRtdnRQMWF4aGtKX2lSVGlFMjRFSWVwZnlZRGZNa0ZnTUV6SXRGczYwWWJVRjR6LWJkTDI0cTM3VDZONVNPZ2JsUUE2YUZwUkl0a0FYMEFkZw?oc=5" target="_blank">Cibus Inc (CBUS) Earnings Dat…
CBUS — Frequently Asked Questions
What is the current share price of Cibus, Inc. (CBUS)?
As of 2026-09-19 21:16 PDT, Cibus, Inc. (CBUS) trades at $1.61 on NasdaqCM. Its 52-week range is $1.16 to $4.05.
What is the market capitalisation of CBUS?
Cibus, Inc. (CBUS) has a market capitalisation of $123.05M on NasdaqCM.
What is the P/E ratio of CBUS?
CBUS trades at a trailing price-to-earnings (P/E) ratio of -1.07. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 8.20.
Is CBUS a good stock to buy?
This page provides a data-driven analysis of Cibus, Inc. (CBUS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.